Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ahmet Sevindik

Advertisement
Set Alert for Articles By Ahmet Sevindik

Latest From Ahmet Sevindik

Turkey Grapples With Spinraza Cost As Patients Seek Access

Families of spinal muscular atrophy patients in Turkey are demanding immediate access to Biogen’s Spinraza following its US approval in December. Its public payer is in discussions over possible reimbursement of the high-priced imported drug but the company is said to have shown no pricing flexibility so far.

Turkey Pricing Debate

Turkish Govt Using Purchasing To Foster Local Generic Production

Facing difficulties in attracting greenfield pharma investments in the production of original and high-tech drugs, the Turkish Government is leveraging its purchasing power for generics to encourage local manufacture in this sector. Faced with the threat of exclusion from reimbursement, some multinationals are now building up their capacity in the country.

Turkey Manufacturing

Turkish Pharmacists Resist Tightening Govt. Grip On Import Procurement

Turkey’s public drugs payer has signed a new agreement with the national Post Office for the distribution of unavailable medicines procured from abroad, starting in May, prompting a strong response from the pharmacists’ groups that now largely control the sizeable business.

Turkey Policy

Alvimedica Readies For Maiden Voyage Into US Drug-Eluting Stent Market

Having started out as a specialist in high-level medtech R&D and manufacturing in Turkey, Alvimedica has evolved to become a player in the interventional cardiology market with a portfolio of stents, balloons and catheters. It now has its eye on the $2.6bn US therapeutic interventional cardiology market for its Cre8 EVO drug-eluting stent.

Cardiology Turkey

2017 Not Looking As Bright As It Should Be For Turkish Pharma

The pharmaceutical industry in Turkey has started 2017 cautiously despite a basically dynamic market and increasing demand for healthcare, with continued pricing and cost pressures, and political and economic instability, likely to dampen new investments.

Turkey Policy & Regulation

Turkish Hospitals' Billion-Dollar Debt A Top Priority For Medtech Suppliers

While many medtech companies are looking at strategies to grow their sales this new year, those that are operating in Turkey look like their focus would be on simply getting paid for what is owed by the country's debt-ridden hospitals.

Turkey Policy
See All
Advertisement
UsernamePublicRestriction

Register